Reed Smith’s Life Sciences Health Industry Group is pleased to offer a 1/2-day CLE covering hot topics and emerging litigation trends for in-house counsel.

Please join us for informative and practical sessions on Product Liability, Government Enforcement, Intellectual Property and Insurance issues impacting our pharmaceutical and medical device clients.

Sessions will include:

• Major Drug and Device Decisions of 2016
  Presented by Eric Alexander (partner, Reed Smith LLP) and Kelly Hibbert (associate, Reed Smith LLP)
• FCA Post-Escobar: Materiality Matters
  Presented by Thomas Suddath (partner, Reed Smith LLP), Brian Himmel (partner, Reed Smith LLP), and Lindsey Harteis (associate, Reed Smith LLP)
• Purple is the New Orange: A Primer on the Biologics-Biosimilars Landscape
  Presented by Lisa Chiarini (partner, Reed Smith LLP) and Rudolf Hutz (counsel, Reed Smith LLP)
• Looking for Law in All the Wrong Places: Perspectives on the Best (and Worst) Product Liability Jurisdictions
  Presented by Rick Fuentes, Ph.D. (jury consultant, R&D Strategic Solutions), Barbara Binis (partner, Reed Smith LLP), Melissa Geist (partner, Reed Smith LLP), and Marilyn Moberg (partner, Reed Smith LLP)
• Regulating Healthcare on a New Wavelength: The FCC’s Role In Wireless Medical Devices
  Presented by Paul Bond (partner, Reed Smith LLP) and Samuel Cullari (counsel, Reed Smith LLP)
• Implied Preemption – It’s Not Just for Generic Drugs Anymore (Plus Off-Label Promotions Update)
  Presented by James Beck (counsel, Reed Smith LLP) and Rachel Weil (counsel, Reed Smith LLP)

This program is geared toward in-house counsel; space is limited.